Aurobindo Pharma gets USFDA nod for infections treatment drug
Aurobindo Pharma has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Azithromycin oral suspension
New Delhi: Drug firm Aurobindo Pharma Thursday said it has received final nod from the US health regulator for its Azithromycin oral suspension used for treatment of infections.
The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Azithromycin oral suspension 100 mg /5 mL and 200 mg/5 mL, Aurobindo Pharma said in a statement.
The product is a generic version of Pfizer Inc’s Zithromax oral suspension, it added.
“The product will be launched in November 2018,” Aurobindo Pharma said.
Azithromycin oral suspension is indicated for the treatment of patients with mild to moderate infections, it added.
According to IQVIA, the approved product has an estimated market size of $71 million for the 12 months ending August 2018, Aurobindo Pharma said.
The company now has a total of 386 abbreviated new drug application (ANDA) approvals (357 final approvals including 19 from Aurolife Pharma LLC and 29 tentative approvals) from the USFDA, it added.
Shares of Aurobindo Pharma were trading at Rs 773.75 per scrip on the BSE, down by 0.58% from its previous close.
- IL&FS secures moratorium against all creditor actions
- PNB plans to sell non-core assets of over ₹8,000 crore this fiscal
- India pitches for review of oil payment terms to stem rupee fall
- MG Motor to drive in electric SUV in India by first half of 2020
- Visa, Mastercard said to miss RBI’s data localization deadline
Editor's Picks »
- Banks turned wary of NBFCs months before IL&FS defaults
- HUL Q2: Rising input costs face off against healthy demand growth
- Q2 results: DMart finally set to face a reality check
- Temporary staffing: Decent employee additions, margin pressures may sustain
- Gujarat relief for Tata Power, Adani Power underlines sector’s harsh reality